Clinical trial · Observational
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
NCT00919477CI-TRIAL-00009027CAMONcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To gather information on the safety of monotherapy of Casodex® tablets 80 mg, targeting prostate cancer patients who have no history of having received treatment by either endocrine therapy (including surgical castration).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Adverse event incidence
- timeFrame
- Time since starting Casodex monotherapy, monthly
Secondary outcomes (2)
- measure
- improvement of prostate cancer using Tumor marker PSA
- timeFrame
- Time since starting Casodex monotherapy, monthly
- measure
- Maintenance of sexual function
- timeFrame
- At 3 months since starting Casodex monotherapy,
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Prostate cancer patients who have no history of receiving endocrine therapy (including surgical castration), and who plan to undergo Casodex® tablets monotherapy for not less than 12 months
References
Publications (0)
Data not yet available
No reference posted for this study.